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The ability to silence genes effectively at the pre-translational level through the use of short 
interfering ribonucleic acid (siRNA) has become a widely studied area since the discovery 
of the RNA interference pathway in 1998. The ability to silence genes at this point in the 
central dogma of cell biology offers the chance for excellent gene knockdown specificity as 
the gene silencing tool is tailored for an exact messenger RNA sequence. There are some 
inherent problems associated with this type of technology which arise from the chemical 
structure of RNA including poor cell permeability due to the polyanionic backbone or due 
to the fact that RNA is a natural substrate for nucleases. In an attempt to mitigate these 
problems there has been considerable focus on chemical modification of siRNAs such as 
alteration of the ribose ring or backbone. Backbone alterations such as abasic alkyl linkers 
have been shown to retain, if not improve, gene-silencing capability while providing a 
means of centrally destabilizing the siRNA duplex, even when occupying the site of the 
catalytic protein, Argonaute2, whose action was thought to be an essential part of the RNA 
interference pathway. This study herein reports the synthesis of novel abasic alkyl linkers 
and an evaluation of their dose-dependent ability to silence genes in vitro while occupying 
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1.0 - Introduction and Literature Review 
1.1 – DNA vs. RNA: The Biomolecules of Life 
 The instructions to all life are written in a language where only four letters are used; 
these letters each represent a specific chemical structure. These compounds form long 
biopolymers which are known as deoxyribonucleic acid (DNA) which form the human 
genome; the ability of genes to be expressed is accomplished through another biopolymer 
known as ribonucleic acid (RNA) [1]. These nucleic acids are repeating units of heterocyclic 
bases appended off of a ribose sugar-phosphate backbone (Figure 1-1). This biopolymer is 
polyanionic due to the phosphate being deprotonated at neutral pH [2]. There are two 
important differences between DNA and RNA. Firstly, in DNA the four nitrogenous bases 
are adenine (A), cytosine (C), guanine (G) and thymine (T); RNA is the same except for 
thymine being replaced by uracil (U). Another difference is that RNA has a hydroxyl group 
at the 2’ position of the ribose ring whereas DNA has only a methylene group at the 2’ 
position [3]. The addition of the 2’ hydroxyl is a very crucial difference between the nucleic 
acids because it imparts different structural conformations. The 2’ hydroxyl forces the 
pentofuranose ring to adopt a C3’-endo conformation, which is the preferred structural 
conformation of RNA and is a result of the gauche effect between the 4’O and 2’OH [4]. 
Whereas DNA primarily exists in a long double stranded form used to contain genetic 
information, RNA tends to exists in shorter single strands that exhibit many biologically 
active forms such as mRNA, miRNA and tRNA [5]. Single stranded RNAs have 
complementary regions that form small double helices which can pack together to form 




Figure 1-1: Structural comparison of RNA and DNA. The sugar numbering is depicted on the 
adenine base on the DNA strand. 
 Both DNA and RNA have the capability of existing in a double stranded form, pairing 
up with another strand to form a duplex. The duplex is held together through the hydrogen 
bonding occurring between to the complementary base pairs; this is known as Watson and 
Crick or canonical base pairing where A bonds with U or T and G bonds with C [7]. The two 
strands are antiparallel (5’ and 3’ ends are reversed) to each other and the resulting duplex 
exists as a double helix [8]. 
 Arguably the most important pathway in molecular biology, involving both DNA and 
RNA, is the conversion of genetic information into functioning molecules such as proteins; 
this pathway is known as the central dogma of molecular biology (Figure 1-2). The 
pathway begins when the double stranded genomic DNA is unwound; at this point one of 
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two things can happen: 1) DNA replication in preparation for cell division or 2) RNA 
production via transcription [9]. Transcription takes the genetic information and changes it 
into messenger RNA (mRNA) which then leaves the cell’s nucleus and associates with 
organelles in the cytoplasm known as ribosomes. The ribosome then creates specific 
proteins by, in essence, ‘reading’ the mRNA sequence [10]. It is possible in some instances 
for RNA to be reverse transcribed back in to single stranded DNA; such is the case with HIV 
which possesses a reverse transcriptase enzyme [11]. Since the 1970’s there has been 
much interest in manipulating gene expression in living cells by targeting this pathway  
 
Figure 1-2: The central dogma in molecular biology. 
for possible gene analysis and therapeutic agents [12]. Traditional therapeutics tend to 
target post-translational molecules such as proteins, whereas oligonucleotides can be made 
with a certain sequence to compliment that of a specific mRNA to target this pathway at the 
pre-translational level, affording a new specific means of gene suppression [13]. There is 
great interest in utilizing this idea as a means to treat diseases which are the result of 
aberrant gene expression such as cancer [14].   
1.2 – The RNA Interference Pathway  
 The RNA interference (RNAi) pathway is highly conserved, ancient in origin and 
exists in a wide variety of organism for the purpose of gene expression regulation [15] and 
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protection from foreign DNA and RNA [16]. This pathway was discovered in 1998 by two 
scientists, Fire and Mello, while they were investigating the effects of using antisense RNAs 
to knock-down the abundant unc-22 mRNA in the model organism C. elegans. Fire and 
Mello unexpectedly stumbled upon the RNAi pathway when obtaining unexpected high 
knock-down with double-stranded RNA (dsRNA)[17]. This opened up a brand new avenue 
in the gene silencing capability of RNA; dsRNA that exhibited gene silencing capability 
became known as short interfering RNA (siRNA) and has rapidly become a widely used tool 
for molecular biology gene knock-down experiments and is being investigated for its 
therapeutic applicability [18].  
1.2.1 - The mechanism of siRNA and RNAi in humans 
 Short interfering RNAs are dsRNA molecules that are typically 19 to 21 base pairs in 
length and possess a definitive two-base pair overhang on the 3’ end of each strand (Figure 
1-3) [19]. This siRNA is first bound by an Argonaute2 protein that is specific for dsRNA that 
is in the A-form helical conformation [20]. Binding of this Argonaute2 protein facilitates the 
assembly of several other proteins, which include a double stranded trans-activated 
binding domain protein (TRBP), Dicer and others; together all of which form the RNA 
induced silencing complex (RISC) [21]. The RISC then chooses a single strand, known as the 
antisense strand, by having TRBP and Dicer assess which strand has the least 
thermodynamically stable 5’ end and the complementary strand becomes degraded [22]. 
When RISC has this single strand it is now in its activated form at which time it seeks out 
mRNA within the cytoplasm that is complementary [23]. When a complementary mRNA 
sequence is located a duplex is then formed between the antisense strand and the mRNA 
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resulting in the mRNA strand in the duplex being cleaved at the phosphodiester bond 
between the base pairs across from the 9th and 10th base pairs counting from the 5’ end of 
the antisense strand [24]. The resulting cleaved mRNA dissociates from RISC and can no 
longer be translated in to the proper protein.  
Figure 1-3: The RNA interference pathway within humans.  
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This pathway is initiated one of two ways: 1) synthetic siRNAs can be directly transfected 
in to cells using transfecting agents such as cationic polymers, this is the route taken for 
siRNAs used as molecular biology tools and therapeutic applications or 2) native long 
endogenous dsRNA is processed by the enzyme Dicer in to siRNA [25]. An example of 
native dsRNA is pre-microRNAs which are expressed from RNA coding genes in the 
genome; the primary transcript becomes processed into the trademark stem-loop and 
enters the cytoplasm converging with the synthetic siRNA pathway at RISC [26]. The 
enzyme Dicer has two distinct RNase III motifs, a dsRNA binding domain and a RNA 
helicase domain [27] which it uses to catalyze the cleavage of long dsRNA. When Dicer was 
knocked down in human HeLa cells it was shown that dsRNA built up in the cytoplasm [28].  
 Another essential enzyme to the RNAi pathway is the Argonaute2 endonuclease 
which carries out a significant portion of the pathway’s catalytic activity including the 
eventual mRNA cleavage [29]. Ago2 also plays a key role in removing the inactive sense 
strand from the duplex [30]. It is not fully understood as to whether Ago2 is complexed 
with DICER and TRBP while the active guide strand is being directed towards its target or 
whether Ago2 is performing RNAi independently [31]. This endonuclease is comprised of 
three main domains; a PAZ on the carboxyl terminus, a PIWI domain on the amino 
terminus and a central Mid section [32] as is shown in (Figure 1-4). The section 
responsible for the catalytic activity of the enzyme is the PIWI domain which resembles the 
RNase H endonuclease [33]. The Mid domain of Ago2 has been identified as the region 
which associates with the phosphorylated 5’ end of the antisense strand while the PIWI 
domain binds to the 5’ region of the antisense strand [34]. The PAZ domain interacts with 




Figure 1-4: Argonaute2 catalytic region with an antisense RNA and its complementary 
mRNA. 
region of the strand [35]. It is important to keep these interacting regions in mind when 
attempting to impart chemical modifications on siRNAs as these interactions need to be 
maintained in order to retain function whether as a molecular biology tool or as a possible 
therapeutic agent [36].  
1.2.2 – Problems with siRNA Therapeutics 
 The use of RNA as a therapeutic agent has been around for a while; it began in the 
late 1970’s when it was demonstrated that simple antisense RNA oligonucleotides could 
directly interfere with mRNA translation within a cell by binding to a complementary 
mRNA strand and preventing the ribosomal assembly necessary for translation [37]. A 
specifically tailored antisense oligonucleotide can inhibit the translation of mRNA of an 
overexpressed gene, as is the case in many cancers, thus mitigating the effects [38]. 
Decades later there are only two antisense oligonucleotide therapeutics that have been 
FDA approved: most recently Mipomersen (marketed as Kynamro in 2013) and before that 
Formivirsen (marketed as Vitravene in 1998) [39]. With decades of research in the field it 
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seems worrisome that only two drugs have made it to market. With siRNAs the situation is 
even bleaker having been around for sixteen years there are no FDA approved drugs. It is 
important to note however that there are others currently in clinical trials [40]. A major 
factor in the delay in the emergence of other therapeutics arises from the structure of RNA 
itself which possesses several noticeable pitfalls when assessing its use as a therapeutic.  
The main issues that need to be taken into consideration are: 1) enzymatic degradation, 2) 
polyanionic nature of RNA at physiological pH and; 3) off-target effects [41].  
 There are mechanisms that exist within every organism that target all nucleic acids 
for degradation, particularly RNA, which results in a shortened duration of activity. This 
occurs due to the presence of exo- and endo-nucleases that exist in the blood serum, of 
which RNA is a natural substrate due to the phosphodiester linkages [42]. Fortunately for 
siRNAs, RNA duplexes are more resistant to nucleases; however unmodified RNA duplexes 
are still readily degraded within serum [43]. In the case of siRNAs it is currently believed 
that an enzyme closely related to ERI-1 is the main catalytic portion of the degradation 
pathway [44]. An interesting trait of this degradation pathway is that it has been shown 
that cleavage of siRNAs typically happens after pyrimidines [43] which could be useful 
when selecting an mRNA sequence to target. Another important note about the 
phosphodiester bond is its susceptibility to hydrolysis at physiological pH since 
phosphorous is oxophilic and the attack of water at its electron deficient center is a 
favourable reaction [45].  Keeping this in mind, it is also possible for the hydroxyl group on 
the ribose sugar 2’ position to perform a nucleophilic attack on the closest phosphorous 
atom in a form of self-hydrolysis [46].  
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 With a pKa close to zero, the hydroxyl group on the phosphodiester linkage is 
deprotonated at physiological pH which means that RNA strands have a polyanionic 
backbone [46]. This severely hinders RNA’s ability to be cell membrane permeable which 
in the end directly affects delivery to cells due to the presence of many negatively charged 
moieties on the surface of the cellular membrane [47]. This large charge density also 
hinders RNA’s ability to associate with serum proteins, such as albumin, resulting in the 
strands becoming heavily hydrated making them easier targets for hydrolysis [48].  
 Since the siRNA antisense strand relies on Watson-Crick base pairing to identify the 
target mRNA it is possible that other mRNA sequences that possess a high degree of 
similarity to the target could accidently be degraded [49]. Duplexes with a mismatch can 
still form RISC tolerable substrates which can result in off-target silencing [49]. This can be 
particularly troublesome if the unintended target belongs to a vital pathway. Sometimes 
when an siRNA is associating with RISC there is an error in strand selection and the active 
RISC is formed with the guide strand resulting in only off target effects [50]. 
 In order to further pursue RNAs as therapeutics these issues need to be addressed. 
There are currently two main avenues being studied: 1) new delivery systems such as 
nanoparticle delivery and 2) chemical modifications to oligonucleotides, which will be the 
main focus of this dissertation herein.  
1.2.3 – Chemical Modifications of siRNAs 
 Organic chemists have been synthesizing chemically modified oligonucleotides for 
decades now with the hopes of finding a biocompatible modification that mitigates the 
pitfalls of RNA whilst retaining potent gene silencing ability. While current modifications 
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do show certain positive features there is currently no universally accepted chemical 
modification that satisfies these criteria so the search for new modifications continues.  
 Looking at the structure of a 21 bp oligonucleotide the thought of performing a 
chemical modification at a specific position seems daunting; however in reality it is quite 
simple using well established nucleic acid synthetic methods which synthesize oligos one 
bp at a time on a controlled-pore glass (CPG) support [51]. One of the most commonly 
utilized method is the dimethoxytrityl (DMT)-phosphoramidite solid phase synthesis [52] 
(Figure 1-5) which uses a 5’ triphenyl alcohol protecting group and a 2’ phosphite group to 
methodically build specific sequences and allowing modifications to be specifically 
incorporated into the oligonucleotide by making modification phosphoramidites.  
 




The solid support (CPG) usually comes with a DMT protected dT base already 
attached to the solid support so the synthesis proceeds in the 3’  5’ direction and is fully 
automated. The initial step is the acid mediated deprotection of the 5’ DMT group (i) using 
trichloroacetic acid which produces a primary alcohol that will couple with the next 
nucleobases [53]. As the arrows show, the trityl cation that will be formed is resonance 
stabilized by the methoxy groups, making it easily cleaved off [53]. Before the subsequent 
base couples it must be activated with ethylthiotetrazole (ii), which is an excellent leaving 
group, which displaces the diisopropylamine group. Phosphorous is oxophilic so the free 
primary alcohol readily attacks the phosphite center of the activated base coupling the two 
nucleobases (iii), the rate of which is greatly increased due to the activation step [54]. RNA 
has a phosphate linkage as opposed to a phosphite so the newly formed phosphite linkage 
needs to be oxidized which is initiated by the nucleophilic attack of phosphorous on iodine 
(iv) [54]. Deprotonation of water by pyridine (v) results in the formation of a nucleophilic 
hydroxide anion which attacks the phosphorous center resulting in a positively charged 
intermediate which is readily deprotonated by another molecule of pyridine (vi) which 
produces the stable phosphate (vii) [53]. At this point the cycle has completed and the 
oligonucleotide can either keep cycling by coupling successive bases or the loop can be 
terminated if the desired sequence has been achieved; cleavage and deprotection results in 
the formation of an oligonucleotide in its native form, not considering incorporated 
modifications (viii).  
 There are a large variety of chemical modifications for oligos with more constantly 
emerging. The types of modifications fall in to one of three categories: 1) backbone 
modifications; 2) ribose sugar modifications and 3) nucleobase modifications [55]. 
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Modifying the backbone has been extensively studied due to the fact that it can allow for 
mitigation of some of the polyanionic nature of an oligo as well as allowing for creation of 
linkages that are resistant to exo- and endo-nucleases [56].  One such example is the 
phosphorothioate (PS) where a sulfur atom is substituted for one of the non-bridging 
oxygen atoms [57] which makes the oligo much more resistant to degradation by 
nucleases. This cost-effective modification is compatible with many oligo synthesis 
protocols and is found in the FDA approved antisense drug Vitravene [58]. The PS linkage 
imparts chirality on to the linkage and one of the stereoisomers is a poor substrate for 
nucleases [59]; diastereoselective syntheses have been described [60] but typically a 
diastereomeric mixture results. Several PS linkages can be incorporated which further 
enhances stability while retaining silencing ability [61]. Silencing ability is lost however 
when this modification is placed within the AGO2 cleavage site as stereochemistry 
introduced by the PS linkage is not tolerated by the catalytic region [62].  
 Sugar modifications are useful for controlling the ribose ring puckering which is a 
crucial physical property of oligonucleotides for binding with complementary sequences, 
duplex conformation and enzyme substrate toleration [63]. The ribose conformation is 
controlled by alteration of the gauche and anomeric effects. For dsRNA, the preferred 
conformation is the C3’-endo/C2’-exo or sometimes referred to as the ‘North’ conformation 
[63]. Many sugar modifications are well tolerated in RNAi with one of the most popular 
ones being the 2’-fluoro modification [64], an RNA mimic. This modification retains the 
desired ‘North’ conformation which can be attributed to the strong gauche effect that arises 
from the 2’-fluorine [65]. The 2’-Fluoro is a modification that is well tolerated in siRNAs in 
both the sense and antisense strands. 
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 The final type of modification is the modification of the nucleobases which has been 
shown to affect the thermal stability of duplexes, mitigate immunostimulation and affect 
off-target effects [66]. A more recent trend in nucleobases modification has seen the 
attachment of fluorescent modifications for the application of studying oligonucleotide 
therapeutics [67]. The fluorescent groups allow for monitoring of the oligos and has 
allowed for the development of enzymatic assays, such as the one developed for RNase H-
mediated cleavage [68]. An example of a nucleobases modification is the 2,4-
difluorotoluene (dFT) which can substitute thymine in DNA and Uracil in RNA [69]. It has 
been shown that this modification when placed in the 5’ region of the guide strand 
increased specificity, increased RNA stacking and an increased binding affinity for RISC 
[70]. Unfortunately, this modification is not well tolerated elsewhere as the duplex 
becomes destabilized as the dFT is unable to hydrogen bond to the complementary base 
[70].  
 Since modifications introduce new chemical functionalities into siRNAs there is 
going to be some changes to the biophysical characteristics of the duplex; two of the 
important ones being the helical conformation and the thermal stability (melting 
temperature, Tm)[71]. The helical conformation must be A-form in order to have activity 
otherwise the siRNA duplex would not be a properly tolerated substrate for RISC [72]. The 
thermal stability is important because if the Tm of the duplex is too low the strands will 
dissociate with greater ease; if siRNA dissociated before RISC association RNAi is unable to 
occur [73]. A decrease in Tm is imparted on to duplexes for most chemical modifications as 
the modifications distort optimal hydrogen bonding or in some cases remove it completely 
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[74]. There are examples of modifications, such as those to the minor groove of the helix, 
that are actually capable of increasing the thermal stability of a duplex [75].  
 
Figure 1-6: Some common chemical modifications to RNA. 
1.3 – Alkyl Linker Modified Nucleic Acids 
 Since there is no universally accepted chemical modification that satisfies the 
criteria for drug design chances are if an siRNA therapeutic obtains FDA approval it will 
have some new type of modification never seen before. In Figure 1-6 examples of backbone 
modifications are shown by the phosphorothioate and the phosphonoacetate 
modifications. Another type of backbone modification is also present, the abasic alkyl 
spacers. These spacers are a relatively new and are very intriguing because of the way 
these spacers are surprisingly tolerated within the central region of siRNAs unlike many 
other modifications [76]. Even when spanning the AGO2 catalytic region of the sense 
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strand, effective silencing is still observed even though the alkyl linkages are most likely 
not cleaved whilst retaining potency close to wild-type [77]. Even more intriguing is that 
the incorporation of these modifications within the central region of the sense strand 
reduces off-target effects without reducing silencing activity [78]. The linker has no rigidity 
to it which allows RNA duplexes to maintain their active A-helix conformation [79]. An 
appealing feature about these linkers if they were to ever make it in to pharma is that the 
synthesis of the phosphoramidites is simple and very cost-effective. Since this type of 
backbone modification is relatively new there has not been much variety in the types of 
abasic linkers that have been tested; the two major types are: 1) simple alkyl chains and 2) 
polyethylene glycol chains [79]. This is where the knowledge gap begins; there is currently 
no peer-reviewed literature on simple abasic alkylamino chain spacers that have been 
modified and incorporated in to RNA for gene silencing purposes.  
 
Figure 1-7: The structure of Sobczak’s amine linker phosphoramidite and the easy single 
step modification that is possible. 
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A study in 2011 by Sobczak et al., showed that siRNAs with simple alkyl-amino linkages 
between bases retained excellent gene silencing ability. The linker simply replaced the 
phosphodiester bond between bases, which offers an easy modification site on the 
secondary amine (Figure 1-7). Although this is an excellent novel type of modifiable 
linkage its progress in biological studies has been hindered due to the complex synthesis. 
Using this type of modification approach on a secondary amine, an abasic linker with 
evenly dispersed secondary amines (Figure 1-8) could be a potential pathway to begin 
investigating how modified abasic spacers behave in RNAi.  
 
Figure 1-8: New amine dispersed abasic linkers. 
1.3.1 – Modification Purpose and Benefits 
 The readily available starting material can be turned in to a phosphoramidite for 
RNA synthesis in a few easy steps. This linker affords the ability to test many easy and 
readily usable modifications in a timely and cost effective manner as the synthesis is cheap, 
straightforward and comparatively high yielding compared to introducing modifications on 
Sobczak’s linker, as an example. The addition of this modification would replace two base 
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pairs (Figure 1-9) and with the introduction of this linker new favourable characteristics 
are imparted up an RNA strand.  
 
Figure 1-9: Structural representation of the new propargyl modified linker in an RNA 
duplex at physiological pH. 
 The first noticeable trait of this linker is that both tertiary amines are protonated at 
physiological pH. This is an excellent feature for addressing cell delivery; as mentioned 
earlier there is electrostatic repulsion between oligonucleotides and the surface of cell 
membranes. Not only does this linker introduce two positive charges, it also removes a 
negatively charged phosphodiester which further decreases the polyanionic nature. The 
fine tuning of adding multiple linkers could afford a very simple means of significantly 
reducing the polyanionic nature of nucleic acid strands while retaining activity.  
 As the two previous figures depict, attaching simple modifications to this new linker 
scaffold is very simple; this provides a new platform from which more intricate chemistry 
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can be done. Figure 1-9 shows the modified linker with a terminal propargyl group. This 
alkyne could be easily reacted to attach biological moieties using the well-established 
azide-alkyne click reaction which has been proven as a biocompatible way of attaching 
biological moieties [80]. Biomolecules such as cholesterol are commonly seen affixed to 
siRNAs; however these are usually 3’ modifications. Another attractive feature of affixing 
biological moieties is that with an abasic linker such as this one, the molecular weight 
doesn’t increase much (if at all) compared to wild type, which is beneficial as smaller 
molecules have easier times traversing cellular membranes simply due to their size [81]. 
 The introduction of this linker into an siRNA duplex would undoubtedly decrease 
the thermal stability of the duplex as two of the base pairs are removed therefore removing 
the stabilizing hydrogen bonding at the site of the modification. An interesting study in 
2010 by Maier et al., showed that destabilization using base pair mismatches in the central 
region of the sense strand in siRNAs (bp 9 – 12) could significantly improve their potency 
[82]. By replacing central region mismatched with this linker, it is plausible that the 
introduction of destabilization occurring would be beneficial in this case as well. What is 
now really interesting about placing this modification near the central region is that if 
activity is retained it will open up a new avenue in exploring modifications in and around 
the Argonaute2 cleavage site.  
 With the literature showing a lot of promise for alkyl spacers in siRNAs, there are 
more than enough reasons to pursue developing new modifications based around these 




1.4 – Project Definition  
 With the excellent ability to silence genes at the pre-translational level having many 
uses there is promise for siRNAs in the near future, such as being used as therapeutic 
agents to treat genetic diseases. These siRNA therapeutics will most likely have some sort 
of synthetic chemical modification(s). As the library of chemical modifications keeps 
growing new siRNAs will be synthesized that have enhanced cellular permeability, lower 
degradation by nucleases and reduced off-target effects.  
This project will involve the incorporation of an abasic alkyl spacer with secondary 
nitrogen atoms into RNA oligonucleotides. A more simplified version of this type of spacer 
was previously studied by Dr. Tim Efthymiou and this is an extension of his work. The 
modification will be synthesized using organic chemistry and synthetically incorporated 
into RNA oligonucleotides. The synthesized RNA strands will be annealed with their 
compliment sequence strands to form siRNA duplexes. The siRNA strands will undergo 
hybridization testing to assess how the modifications affect the thermal stability of the RNA 
duplex as well as to whether the introduction of this modification alters the helical 
conformation of the native alpha helical structure of wt RNA duplexes.  The siRNAs will also 
have their ability to silence gene expression assessed firstly using the dual luciferase 
reporter system which is an exogenous target. This bioassay is a screening method that will 
be used to identify certain siRNA duplexes that show promise with this chemical 
modification is certain positions. The top performing strands in the luciferase assay will be 
identified and used as a screen to select which anti-BCL2 strands should be tested. The 
effectiveness of these strand’s ability to effectively knock down the BCL2 gene will be  
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studied using qRT-PCR which provides a more clinically relevant assessment of the actual 















2.0 - Experimental  
2.1 – General Synthetic Method 
All chemicals and solvents were purchased from commercial sources without further 
purification unless indicated otherwise. Amine bases, such as TEA, were distilled under N2 
gas using a simple glass still head before their usage. All flash chromatography purifications 
were done using Silicycle Siliaflash 60 (230-400 mesh). 1H, 13C and 31P NMRs were 
recorded in CDCl3 using an Oxford AS400 (400 MHz) NMR spectrometer. High resolution 
mass spectrometry was performed using a Micromass AutoSpec Ultra Magnetic sector 
mass spectrometer.  
2.2 – Synthesis and Characterization of Organic Compounds 
 
2.2.1 – Synthesis of N,N’-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)ethane-1,2-





A solution of N,N’-bis(2-hydroxyethyl)ethandiamine (4.95 g,  33.4 mmol) in 175 ml of 
CH2Cl2 was prepared and allowed to stir for 10 minutes to dissolve the starting material. To 
this was added diisopropylethylamine (14.5 ml, 83.5 mmol) followed by the drop-wise 
addition of a solution of tert-butyldimethylsilylchloride (10.57 g, 70.1 mmol) in 50ml of 
CH2Cl2 over several minutes. The reaction was left stirring at room temperature for 12 
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hours.  A saturated sodium bicarbonate solution extraction was performed and the organic 
layer was dried with Na2SO4. The organic layer was concentrated in vacuo to afford an oil 
which was purified by silica gel chromatography eluting with a gradient of MeOH/CH2Cl2 
(100% CH2Cl2 to 5% MeOH in CH2Cl2) to afford the title compound as a clear yellow oil 
(8.39 g,  68%); 1H NMR  (400 MHz, CDCl3) δ 0.04 (s, 12H), 0.87 (s, 18H), 2.40 (br. s, 2H), 
2.72 (t, 4H, J = 5.86 Hz), 2.76 (s, 4H), 3.70 (t, 4H, J = 5.5 Hz); 13C NMR (125 MHz, CDCl3) δ – 
5.36, 18.26, 25.90, 53.13, 57.54, 62.82, 77.85; ESI-HRMS (ES+) m/z calculated for 
C18H44N2O2Si2: 377.3014, found 377.3023 [M+H]+ 
2.2.2 – Synthesis of N,N’-diallyl-N,N’-bis(2-((tert-




A solution of 1 (2.03 g,  5.395 mmol) in 50 ml of CH2Cl2 was prepared and allowed to cool in 
an ice bath while a mineral oil-sodium hydride dispersion (60% NaH) (0.68 g, 16.2 mmol) 
was washed three times with hexanes to remove as much mineral oil as possible. The 
sodium hydride was then slowly added to the solution of 1. Once the reaction mixture was 
no longer bubbling; allyl bromide (1.16 ml, 13.5 mmol) was added over the course of 3 
minutes. The reaction was gradually warmed to room temperature then left to stir for 6 
hours and was then extracted with saturated sodium bicarbonate. The organic layer was 
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collected and dried with Na2SO4 then concentrated in vacuo to afford an oil which was 
purified using silica gel chromatography eluting with a gradient of  Hexanes/EtOAc (100% 
Hexanes to 30% EtOAc in Hexanes) to afford the title compound as a yellow oil (2.46 g, 
74%); 1H NMR (400 MHz, CDCl3) δ 0.05 (s, 12H), 0.89 (s, 18H), 2.59 (s, 4H), 2.61 (t, 4H, J = 
7.03 Hz), 3.15 (d, 4H, J = 6.3 Hz), 3.67 (t, 4H, J = 6.6 Hz), 5.13 (dd, 4H, J = 9.8 Hz), 5.84 (m, 
2H)  : 13C NMR (125 MHz, CDCl3) δ  -5.29, 18.32, 25.95, 52.73, 56.38, 58.58, 61.90, 117.13, 
135.97; ESI-HRMS (ES+) m/z calculated for C24H52N2O2Si2 468.3567,  found 468.3498 
[M+H]+ 





To a solution of 2 (0.59 g, 1.42 mmol) in 10ml of THF was added 1.0M 
tetrabutylammonium fluoride (4.96 ml, 4.96 mmol) over 3 minutes. The reaction mixture 
was left stirring at room temperature for 4.5 hours at which point TLC revealed 
consumption of the starting material 2 (Rf = 0.92 in 15% MeOH in CH2Cl2) . The reaction 
mixture was concentrated in vacuo which produced a thick yellow oil which was further 
purified using silica gel chromatography eluting with a gradient of MeOH/CH2Cl2 (2% 
MeOH in CH2Cl2 to 5% MeOH in CH2Cl2) to afford the title compound as a thick yellow oil 
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(0.30 g, 92%); 1H NMR (400 MHz, CDCl3) δ 2.70 (m, 8H), 3.27 (d, 4H, J = 6.6 Hz), 3.66 (t, 4H, 
J = 5.1 Hz), 5.23 (dm, 4H, J = 11.7 Hz), 5.91 (m, 2H): 13C NMR (125 MHz, CDCl3) δ  51.62, 
55.61, 58.18, 59.86, 118.44, 134.58; ESI-HRMS (ES+) m/z calculated for C12H24N2O2: 
229.1911, found 229.1920 [M+H]+ 
2.2.4 – Synthesis of 2-(allyl(2-(allyl(2-(bis(4 -





To a solution of 3 (0.61 g, 2.61 mmol)in 30 ml of CH2Cl2  was added diisopropylethylamine 
(0.37 ml, 2.09 mmol) followed by the drop-wise addition of 4,4’-dimethoxytrityl chloride 
(0.71 g, 2.10 mmol) in 5 ml of CH2Cl2 over 10 minutes. The reaction was left to stir 
overnight at which time the reaction became bright yellow. The reaction was extracted 
with saturated sodium bicarbonate and the organic layer was collected and dried with 
Na2SO4. The organic layer was concentrated in vacuo to produce an orange- yellow oil 
which was further purified using silica gel chromatography eluting with a gradient of 
Hexanes/EtOAc (50% hexanes in EtOAc  to 10% hexanes in EtOAc) to afford the title 
compound as an oil (0.63 g, 46 %); 1H NMR (400 MHz, CDCl3) δ 1.23 (s, 1H), 2.67 (m, 4H), 
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2.76 (t, 2H, J = 5.5 Hz), 2.87 (t, 2H, J = 5.7 Hz), 3.20 (m, 4H), 3.26 (t, 2H, J = 5.6 Hz), 3.55 (t, 
2H, J = 4.7 Hz), 3.75 (s, 6H), 5.14 (dd, 4H, J = 10.2 Hz), 5.83 (m, 2H), 6.8 (dt, 4H, J = 9.4 Hz) , 
7.17-7.27 (m, 7H), 7.39 (m, 2H) ; 13C NMR (125 MHz, CDCl3) δ 29.64, 50.45, 51.44, 52.78, 
55.18, 55.58, 57.25, 57.84, 59.03, 60.39, 86.55, 113.11, 126.78, 127.76, 127.82, 129.92,  
133.62, 135.89, 144.68, 158.46; ESI-HRMS (ES+) m/z calculated for C33H42N2O4: 530.3113, 
found 530.3183 [M+H]+  
2.2.5 – Synthesis of 2-(allyl(2-(allyl(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)amino)ethyl)amino)ethyl (2-cyanoethyl) 




A solution of 4 (0.33 g, 0.63 mmol) in 10 ml of dry CH2Cl2 was prepared in a flame dried 
round bottom flask under a N2(g) atmosphere. Freshly distilled diisopropylethylamine (0.55 
ml, 3.16 mmol) was added via an inert transfer. 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (0.42 ml, 1.89 mmol) was added to the reaction over 15 
seconds. The reaction proceeded for 3 hours at which point TLC analysis indicated 
consumption of the starting material 4 (Rf = 0.18 in EtOAc). The reaction mixture was 
concentrated in vacuo producing a yellow oil which was further purified using silica gel 
chromatography eluting with a gradient of Hexanes/EtOAc (20% EtOAc in hexanes to 50% 
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EtOAc in hexanes, with each mobile phase having 2% triethylamine) to afford the title 
compound as a clear oil (0.45 g, 71%); 1H NMR (400 MHz, CDCl3) δ 1.18 (m, 12H), 2.57 (m, 
6H), 2.70 (m, 5H), 3.14 (m, 6H), 3.61 (m, 3H), 3.80 (s, 6H), 5.16 (m, 4H), 5.83 (m, 2H), 6.82 
(d, 4H, J = 9 Hz), 7.20 – 7.35 (m, 7H), 7.45 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 20.27, 
24.62, 42.93, 52.66, 54.14, 55.18, 58.27, 61.65, 62.23, 85.98, 112.99, 117.25, 126.58, 127.69, 
128.19, 130.00, 135.79, 136.51, 145.21, 158.33; 31P NMR (125 MHz, CDCl3)δ 147.64; ESI-
HRMS (ES+) m/z calculated for C43H62N3O5P: 730.4124, found  647.3183 [M+H]+ 
(Hydrolyzed product). 
2.2.6 – Synthesis of N,N’-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)-N,N’-di(prop-2-yn-




A solution of 1 (5.07 g, 13.47 mmol) in 50 ml of dry CH2Cl2 was prepared in flame dried 
glassware sealed with a septum under a N2(g) atmosphere. To this was added 
diisopropylethylamine (7.1 ml, 40.4 mmol) that had been freshly distilled under N2(g) using 
a syringe and needle. An anhydrous transfer of propargyl bromide (80% wt/ml solution in 
toluene) (3.1 ml, 33.7 mmol) to the reaction was accomplished and this reaction was 
stirred for 12 hours at room temperature while remaining under an N2(g) atmosphere. The 
reaction solution was extracted with saturated sodium bicarbonate. The organic layer was 
collected and dried with Na2SO4 and was subsequently dried in vacuo to afford an oil which 
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was further purified using silica gel chromatography eluting with a gradient of 
hexanes/EtOAc (100% hexanes to 20% EtOAc in Hexanes) to afford the title compound as a 
dark yellow oil (5.36 g, 88%); 1H NMR (400 MHz, CDCl3) δ 0.00 (s, 12H), 0.84 (s, 18H), 2.11 
(s, 2H), 2.61 (m, 8H), 3.44 (t, 4H, J = 1.6 Hz), 3.61 (t, 4H, J = 6.3 Hz); 13C NMR (125 MHz, 
CDCl3) δ  -5.29, 18.32, 25.95, 52.73, 56.38, 58.58, 61.92, 117.13, 135.97; ESI-HRMS (ES+) 
m/z calculated for C24H48N2O2Si2: 453.3327 found 453.3325 [M+H]+ 
2.2.7 – Synthesis of 2,2'-(ethane-1,2-diylbis(prop-2-yn-1-ylazanediyl))bis(ethan-1-
ol) – Compound (7) 
 
(7) 
A solution of 5 (1.79 g, 3.95 mmol) in 10 ml THF had 1.0M tetrabuytlammonium fluoride 
(13.8 ml, 13.8 mmol) added drop-wise over the course of 3 minutes. The reaction mixture 
was left stirring at room temperature for 5 hours, at which point TLC revealed 
consumption of the starting material 5 (Rf = 0.72 in EtOAc). The reaction mixture was 
concentrated in vacuo which produced a dark yellow oil which was further purified using 
silica gel chromatography eluting with a gradient of MeOH/CH2Cl2 (2% MeOH in CH2Cl2 to 
10% MeOH in CH2Cl2) to afford the title compound as a thick yellow oil (0.82 g, 93%); 1H 
NMR (400 MHz, CDCl3) δ 2.23 (s, 2H), 2.74 (m, 8H), 3.49 (s, 4H), 3.62 (t, 4H, J = 5.1 Hz) ; 13C 
NMR (125 MHz, CDCl3) δ 42.38, 49.75, 54.60, 58.80, 72.96, 77.78; ESI-HRMS (ES+) m/z 
calculated for C12H20N2O2: 225.1598,  found 225.1598 [M+H]+ 
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2.2.8 – Synthesis of 2-((2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-




A solution of 7 (0.54 g, 2.41 mmol) in 30 ml of CH2Cl2 was added diisopropylethylamine 
(0.34 ml, 1.93 mmol) which was left to stir. Another solution of 4,4’-dimethoxytrityl 
chloride in 5 ml of CH2Cl2 was prepared and was subsequently added to the solution being 
stirred drop-wise over 10 minutes. The reaction was left to stir overnight at which point it 
was extracted with saturated sodium bicarbonate. The organic layer was collected and 
dried with Na2SO4 and concentrated in vacuo to produce a dark oil which was further 
purified using silica gel chromatography eluting with a gradient of Hexanes/EtOAc (20% 
EtOAc in Hexanes to 100% EtOAc) to afford the title compound as a dark oil (0.56 g, 46%); 
1H NMR (400 MHz, CDCl3) δ 1.27 (s, 1H), 2.19 (dt, 2H, J = 14.85 Hz), 2.67 (m, 6H), 2.79 (t, 
2H, J = 5.9 Hz), 3.24 (t, 2H, J = 5.7 Hz), 3.41 (m, 2H), 3.47 (m, 2H), 3.52 (t, 2H, J = 5.3 Hz), 
3.80 (s, 6H), 6.84 (dt, 4H, J = 8.6 Hz), 7.20-7.35 (m, 7H), 7.44-7.48 (m, 2H); 13C NMR (125 
MHz, CDCl3) δ 42.24, 42.70, 50.26, 51.49, 53.20, 54.38, 55.01, 58.80, 61.67, 72.42, 76.13, 
85.89, 112.73, 126.33, 127.42, 127.87, 129.70, 136.03, 144.75, 158.06; ESI-HRMS (ES+) m/z 
calculated for C33H38N2O4: 527.2904,  found 527.2899 [M + H]+ 
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2.2.9 – Synthesis of 2-((2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-
2-yn-1-yl)amino)ethyl)(prop-2-yn-1-yl)amino)ethyl (2-cyanoethyl) 




A solution of 8 (0.36 g, 0.68 mmol) in 10 ml of dry CH2Cl2 was prepared using flame dried 
glassware under a N2(g) atmosphere. To this solution was added freshly distilled 
diisopropylethylamine (0.59 ml, 3.40 mmol). 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (0.45 ml, 2.04 mmol) was added over 15 seconds and 
then the reaction was stirred for 2.5 hours at which point TLC analysis showed 
consumption of the starting material, 8 (Rf = 0.88 in EtOAc). The reaction was concentrated 
in vacuo affording a yellow oil which was further purified using silica gel chromatography 
eluting with a gradient of Hexanes/EtOAc (20% EtOAc in Hexanes to 50% EtOAc in 
Hexanes keeping 2% TEA with each mobile phase) affording the title compound as a clear 
oil (0.35 g, 70.5%); 1H NMR (400 MHz, CDCl3) δ 1.29 (m, 12H), 2.19 (dt, 2H, J = 10.94 Hz), 
2.64 (m, 8H), 2.78 (m, 6H), 3.16 (t, 2H, J = 5.9 Hz), 3.46 (m, 5H), 3.79 (s, 6H), 6.82 (dt, 4H, J = 
8.6 Hz), 7.20-7.35 (m, 7H), 7.44-7.48 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 20.32, 21.20, 
22.96, 24.52, 25.89, 43.07, 45.24, 47.65, 52.04, 53.87, 55.16, 58.51, 62.36, 72.93, 79.03, 
86.01, 113.00, 117.62, 126.57, 128.15, 129.98, 136.40, 145.13, 158.32; 31P NMR (125 MHz, 
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CDCl3) δ 147.91; ESI-HRMS (ES+) m/z calculated for C42H55N4O5P 726.3911,  found 
644.2881 [M+H]+ (Hydrolyzed product). 
 
2.2.10 – Synthesis of N,N'-(ethane-1,2-diyl)bis(N-(2-((tert butyldimethylsilyl) 




To a solution of 1 (0.48 g, 1.28 mmol) in 15 ml of CH2Cl2 was added 4,4-
dimethylaminopyridine (DMAP) (0.08 g, 0.67mmol) and this mixture was stirred until both 
reagents fully dissolved. To this solution was added acetic anhydride (0.38 ml, 3.99 mmol) 
and the resulting mixture was left to stir for 20 hours at which point the reaction was 
extracted with saturated sodium bicarbonate. The organic layer was collected and dried 
with Na2SO4 which was concentrated in vacuo to afford a yellow oil which was further 
purified using silica gel chromatography eluting with a gradient of MeOH/CH2Cl2 (2% 
MeOH in CH2Cl2 to 5% MeOH in CH2Cl2) to afford the title compound as a white-yellow 
powder. (0.56 g, 93%); 1H NMR (400 MHz, CDCl3) δ 0.03 (s, 12H), 0.87 (s, 18H), 2.12 (s, 
6H), 3.46 (m, 8H), 3.73 (t, 4H, J = 5.5 Hz); 13C NMR (125 MHz, CDCl3) δ -5.55, 18.16, 21.72, 
25.80, 43.22, 51.23, 60.77, 171.72: ESI-HRMS (ES+) m/z calculated for C22H48N2O4Si2: 








To a solution of 10 (1.02 g, 2.21 mmol) in 10 ml of THF was added triethylamine 
trihydrofluoride (0.51 ml, 3.10 mmol) drop-wise over 5 minutes. The resulting reaction 
mixture was allowed to stir at room temperature for 3 hours at which point TLC analysis 
indicated the consumption of the starting material, 10 (Rf = 0.79 in 15% MeOH in CH2Cl2). 
The reaction was concentrated in vacuo to afford an pale yellow oil which was further 
purified using silica gel chromatography eluting with a gradient of MeOH/CH2Cl2 (5% 
MeOH in CH2Cl2 to 20% MeOH in CH2Cl2) to afford the title compound as a pale golden 
coloured oil (0.47 g, 92%); 1H NMR (400 MHz, CDCl3) δ 2.11 (s, 6H), 3.50 (m, 8H), 3.79 (t, 
4H, J = 5.5 Hz); 13C NMR (125 MHz, CDCl3) δ 21.87, 46.19, 53.40, 60.27; ESI-HRMS (ES+) m/z 











2.2.12 – Synthesis of N-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-N-(2-(N-




A solution of 11 (1.12 g, 4.82 mmol) in 30 ml of CH2Cl2 had triethylamine (0.34 ml, 3.35 
mmol) added to it and the resulting mixture was allowed to stir for 10 minutes to dissolve 
the starting material. Meanwhile, another solution of 4,4’-dimethoxytrityl (0.98 g, 2.89 
mmol) in  5 ml of CH2Cl2 was prepared and added drop-wise to the first solution over a 
period of 10 minutes. The reaction was then left to stir at room temperature overnight at 
which point the reaction was extracted with saturated sodium bicarbonate. The organic 
layer was collected and dried with Na2SO4 and concentrated in vacuo to afford a yellow oil. 
This oil was further purified using silica gel chromatography eluting with a gradient of 
MeOH/CH2Cl2 (2% MeOH in CH2Cl2 to 10% MeOH in CH2Cl2) to afford the title compound as 
a bright yellow oil (1.13 g, 44%); 1H NMR (400 MHz, CDCl3) δ 2.13 (m, 6H), 3.27 (m, 2 H), 
3.37-3.64 (m, 8H), 3.70-3.84 (m, 8H), 6.84 (m, 4H), 7.17-7.33 (m, 7H), 7.36-7.41 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ 21.96, 46.90, 53.95, 55.23, 60.44, 81.37, 86.68, 113.12, 127.02, 
127.76, 129.12, 129.95, 135.73, 139.51, 147.37, 158.52, 172.92; ESI-HRMS (ES+) m/z 
calculated for C31H38N2O6: 557.2622,  found 557.2611 [M+H]+ 
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2.2.13 – Synthesis of 2-(N-(2-(N-(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)acetamido)ethyl)acetamido)ethyl (2-




A solution of 12 (0.12 g, 0.21 mmol) in 8 ml of dry CH2Cl2 was prepared in flame dried 
glassware. To this was added freshly distilled triethylamine (0.15 ml, 1.03 mmol) and the 
reaction was placed under a N2(g) atmosphere. 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (0.14 ml, 0.56 mmol) was added over 15 seconds and 
then the reaction was stirred at room temperature for 3.5 hours at which point TLC 
analysis indicated consumption of the starting material, 12 (Rf = 0.28 in EtOAc wth 2% 
TEA). The reaction was then concentrated in vacuo which produced a yellow oil. This oil 
was then further purified using silica gel chromatography eluting with a gradient of 
Hexanes/EtOAc (50% Hexanes in EtOAc to 100% EtOAc keeping 2% TEA for each mobile 
phase) to afford the title compound as a clear oil (0.11 g, 71%); 1H NMR (400 MHz, CDCl3) δ 
1.26 (m, 12H), 2.13 (m, 6H), 3.27 (m, 2H), 3.36-3.66 (m, 8H), 3.72 (m, 1H), 3.81 (s, 6H), 
6.79-6.86 (m, 4H), 7.17-7.33 (m, 7H), 7.37 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 17.01, 
20.18, 21.97, 22.54, 23.61, 24.91, 25.52, 42.77, 42.93, 46.30, 47.06, 49.74, 51.13, 53.54, 
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54.18, 55.70, 58.78, 58.94, 62.01, 62.86, 72.44, 78. 31, 86.08, 113,59, 118.29, 126.97, 
127.95, 128.04, 129.67, 136.72, 145.83, 158.49, 172.41; ESI-HRMS (ES+) m/z calculated for  
C40H55N4O7P: 734.3881, found 651.2703 [M+H]+ (Hydrolyzed Product) 
2.2.14 – Synthesis of (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-
methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-




To a solution of cholesterol (2.14 g, 5.81 mmol) in 15 ml of CH2Cl2 was added 
triethylamine(0.88 ml, 8.71 mmol) followed by mesylchloride (0.80 g , 6.97 mmol). The 
reaction was left stirring for 16 hours at which point the reaction was concentrated in 
vacuo to produce a white solid which was purified further using silica gel chromatography 
eluting with a gradient of EtOAc/Hexanes (100% Hexanes to 25% EtOAc in Hexanes) to 
afford the title compound as a white crystalline powder (2.59 g, 96%, Rf = 0.77 in 25% 
EtoAc in hexanes). NMR shifts as reported by (Krishna and Verma, 2011), 1H NMR (400 
MHz, CDCl3) δ  0.64 (s, 6H), 0.82 (d, 3H), 0.87 (d, 3H), 0.98 (s, 6H), 1.03-1.15 (m, 5H), 1.22 
(d, 2H), 1.30-1.34 (m, 3H), 1.41-1.53 (m, 9H), 1.75-1.81 (m, 1H), 1.85-1.88 (dd, 1H), 1.93-
2.04 (m, 2H), 2.43-2.51, (m, 2H), 2.97 (s, 3H), 4.48 (s, 1H), 5.37 (s, 1H); 13C NMR (125 MHz, 
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CDCl3) δ 19.4, 20.7, 22.7, 23.2, 24.6, 27.3, 27.7, 28.1, 29.9, 30.0, 31.9, 35.8, 36.1, 36.76, 37.2, 
37.7, 38.6, 39.9, 44.0, 50.8, 55.9, 56.49, 82.0, 123.69, 138.53. 
 
2.2.15 – Synthesis of (3R,8S,9S,10R,13R,14S,17R)-3-azido-10,13-dimethyl-17-((R)-6-
methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthrene – Compound (15) 
 
(15) 
To a solution of 14 (1.04 g, 2.18 mmol) in 50ml DMF was added sodium azide (0.71 g, 10.9 
mmol). The round bottom flask was then equipped with a condenser column and the 
reaction was warmed to 75 °C where it proceeded for 24 hours. The reaction was cooled to 
room temperature and subsequently concentrated in vacuo which produced a white 
powder which was further purified using silica gel chromatography eluting with hexanes to 
afford the title compound as a white-yellow crystalline powder (0.56 g, 62%, Rf = 0.91 in 
25% EtOAc in hexanes) NMR shifts as reported by (Krishna and Verma, 2011), 1H NMR 
(400 MHz, CDCl3) δ 0.60 (s, 6H), 0.79 (d, 3H), 0.84 (d, 3H), 0.93 (s, 6H), 0.97-1.04 (m, 5H), 
1.18 (d, 2H), 1.25-1.27 (m, 3H), 1.36-1.46 (m, 9H), 1.5 (s, 1H), 1.76-1.78 (dd, 2H), 1.92-1.95 
(m, 2H), 2.16-2.21 (m, 2H), 5.27 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 19.4, 20.7, 22.7, 23.2, 
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24.6, 27.3, 27.7, 28.1, 29.9, 30.0, 31.9, 35.8, 36.1, 36.76, 37.2, 37.7, 39.9, 44.0, 50.8, 55.9, 
56.49, 56.77, 121.76, 140.70. 
2.2.16 – Synthesis of 2,2'-(prop-2-yn-1-ylazanediyl)bis(ethan-1-ol) – Compound (16) 
 
(16) 
To a solution of diethanolamine (9.44 g, 89.8 mmol)in 150 ml of CH2Cl2 on ice was added 
anhydrous potassium carbonate (62.1 g, 449 mmol) with vigorous stirring. Once the 
solution was cooled the dropwise addition of propargyl bromide (80% wt/wt, 10.0 ml, 89.8 
mmol) was carried out over 5 minutes. The reaction was then left to stir for 60 hours, 
allowing the ice bath to melt gradually bringing the reaction up to room temperature. The 
reaction mixture was then filtered using a sintered glass funnel to remove the potassium 
carbonate. The filtrate was concentrated in vacuo to produce a dark amber oil which was 
further purified using silica gel chromatography eluting with CH2Cl2 to 10% MeOH in 
CH2Cl2 to produce a clear amber oil (4.15 g, 32.2%), 1H NMR (400 MHz, CDCl3) δ 2.20 (t, 1H, 
J = 2.4 Hz), 2.72 (t, 4H, J = 5.2 Hz), 3.47 (s, 2H), 3.62 (t, 4H, J = 5.2 Hz); 13C NMR (125 MHz, 






2.2.17 – Synthesis of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-




To a solution of 14 (1.98 g, 13.8 mmol) in 25 ml of CH2Cl2 was added triethylamine (1.73 
ml, 1.24 mmol) followed by the dropwise addition of 4,4’ – dimethoxytriphenylmethyl 
chloride (3.74 g, 11.0 mmol) in 5 ml of CH2Cl2. The reaction mixture was left to stir 
overnight at room temperature after which it was extracted with a saturated NaHCO3 
solution. The organic layer was collected and dried with Na2SO4 followed by the 
concentration in vacuo to produce a green-yellow oil which was further purified by silica 
gel chromatography eluting with a gradient of CH2Cl2 to 10%MeOH in CH2Cl2 to produce a 
clear yellow oil (2.83 g, 45.9%), 1H NMR (400 MHz, CDCl3) δ 2.19 (t, 1H, J = 6 Hz), 2.73 (t, 
2H, J = 5.6 Hz), 2.80 (t, 2H, J = 5.6 Hz), 3.19 (t, 2H, J = 6 Hz), 3.44 (d, 2H, J = 2.4 Hz), 3.59 (t, 
2H, J = 5.2 Hz), 3.80 (s, 6H), 6.84 (dt, 4H, J = 8.8 Hz), 7.21 (m, 1H, J = 7.6 Hz), 7.30 (td, 2H, J = 
7.6 Hz), 7.34 (dt, 4H, J = 8.8 Hz), 7.45 (d, 2H, J = 8 Hz); 13C NMR (125 MHz, CDCl3) δ 42.77, 
52.57, 55.20, 55.65, 56.57, 61.95, 72.82, 78.83, 86.21, 113.07, 126.71, 127.78, 128.14, 




2.2.18 – Synthesis of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-




To a solution of 17 (204 mg, 0.458 mmol) in 5 ml of anhydrous CH2Cl2 under an N2(g) 
atmosphere was added freshly distilled triethylamine (0.32 ml, 2.29 mmol). After warming 
to room temperature in a desiccator, 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite 
(0.31 ml, 1.38 mmol) was added to the reaction mixture which stirred for 2 hours. The 
reaction mixture was then concentrated in vacuo to produce a cloudy oil which was further 
purified using silica gel chromatography eluting with a gradient of 20% EtOAc in hexanes 
to 80% EtOAc in hexanes while maintaining a 2% triethylamine for each concentration. The 
product was isolated as a clear oil (0.12 g, 41.2%) , 1H NMR (400 MHz, CDCl3) δ 1.17 (dd, 
12H, J = 9.6 Hz), 2.19 (t, 1H, J = 2.4 Hz), 2.56 (m, 2H), 2.81 (dt, 4H, J = 14.2 Hz), 3.16 (t, 2H, J 
= 6.4 Hz), 3.46 (d, 2H, J = 1.2 Hz), 3.58 (m, 2H), 3.69 (m, 2H), 3.78 (m, 2H), 3.79 (s, 6H), 6.82 
(dt, 4H, J = 9.2 Hz), 7.20 (tt, 1H, J = 7.2 Hz), 7.28 (t, 2H, J = 8 Hz), 7.34 (dt, 4H, J = 8.8 Hz), 
7.46 (d, 2H, J = 7.2 Hz); 13C NMR (125 MHz, CDCl3) δ 20.29, 24.51, 24.56, 42.94, 43.06, 43.60, 
53.96, 56.15, 58.53, 61.81, 62.42, 72.89, 78.24, 86.01, 112.99, 117.83,  126.59, 127.89, 
129.96, 136.38, 145.12, 158.32.  
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2.2.19 – Synthesis of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)((1-
(((3R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-




To a solution of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-yn-1-
yl)amino)ethan-1-ol (0.62 g, 1.39 mmol) in a 1:1:1 mixture of THF, water and tert-butanol 
was added 15 (1.14 g, 2.77 mmol), copper sulfate pentahydrate (0.17 g, 0.69 mmol) and 
(+)-sodium ascorbate (0.55 g, 2.77 mmol) in that order. The reaction was stirred for 18 
hours at room temperature at which the reaction was the concentrated in vacuo and was 
subsequently extracted using water and CH2Cl2. The organic layer was collected and dried 
with Na2SO4 which produced a green oil. Silica gel chromatography was then used to 
further purify the product using gradient eluting with hexanes/EtOAc (50% hexanes in 
EtOAc to 100% EtOAc)to afford the title compound as a thick clear oil (0.92 g,  77%); 1H 
NMR (400 MHz, CDCl3) δ 0.67 (s, 2H), 0.88 (m, 10H), 0.99-1.19 (m, 11H), 1.24-1.56 (m, 
11H), 1.66 (d, 1H, J = 8.7 Hz), 1.82 (s, 1H), 1.99 (m, 2H), 2.05-2.25 (m, 3H), 2.50 (d, 1H, J = 
8.9 Hz), 2.73 (d, 4H, J = 5.6 Hz), 2.96 (m, 3H), 3.24 (s, 2H), 3.58 (s, 2H), 3.79 (s, 6H), 3.89 (s, 
2H), 4.87 (s, 1H), 5.41 (s, 1H), 6.79-6.86 (m, 4H), 7.17-7.33 (m, 7H), 7.37 (m, 2H), 7.68 (s, 
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1H); 13C NMR (125 MHz, CDCl3) δ 11.51, 17.21, 18.37, 18.95, 20.29, 22.22, 22.48, 23.51, 
23.84, 26.09, 27.67, 27.85, 31.31, 31.56, 32.48, 35.44, 35. 67, 35.86, 36.72, 39.08, 39.18, 
41.90, 49.62, 55.74, 56.14, 112.74, 124.09, 126.40, 127.45, 127.82, 129.66, 135.97, 137.59, 
144.67, 158.06; ESI-HRMS (ES+) m/z calculated for C55H76N4O4: 856.5772 found 879.5783 
[M + Na]+ 








To a solution of 16 (0.33 g, 0.38 mmol) in 10 ml of dry CH2Cl2 was prepared in flame dried 
glassware and put under a N2(g) atmosphere. Freshly distilled triethylamine (0.16 ml, 
1.14mmol) and 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.26 ml, 1.15 mmol) 
were then added to the solution via an anhydrous transfer. The reaction was allowed to stir 
at room temperature for 1.5 hours at which point TLC analysis revealed the consumption of 
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the starting material, 16, (Rf = 0.23 in EtOAc). The reaction mixture was the concentrated in 
vacuo which produced a yellow oil which was further purified using silica gel 
chromatography using gradient elution of Hexanes/EtOAc (50% Hexanes in EtOAc to 100% 
EtOAc) affording the title compound as a clear oil (0.27 g, 68%); 1H NMR (400 MHz, CDCl3) 
δ 0.67 (s, 2H), 0.86-1.56 (m, 44H), 1.66 (m, 2H), 1.79-2.12 (m, 6H), 2.22 (d, 1H, J = 8.9 Hz), 
2.47 – 2.60 (m, 3H), 2.78 (m, 4H), 2.94 (d, 1H, J = 5.6 Hz), 3.18 (s, 2H), 3.62 (m, 4H), 3.70-
3.81 (m, 9H), 3.88 (s, 2H), 4.14 (m, 1H), 5.39 (m, 1H), 6.77-6.87 (m, 4H), 7.16-7.35 (m, 7H), 
7.37 (m, 2H), 7.71 (s, 1H) , ; 13C NMR (125 MHz, CDCl3) δ 11.81, 14.18, 18.68, 19.26, 20.32, 
20.54, 22.54, 22.80, 23.83, 23.89, 23.96, 26.67, 27.99, 31.64, 31.98, 35.75, 36.16, 37.03, 
39.49, 41.80, 42.92, 43.05, 49.94, 54.24, 55.16, 56.38, 56.42, 58.33, 58.51, 60.35, 62.48, 
85.99, 112.99, 117.62, 121.91, 124.20, 126.61, 127.69, 129.98, 136.45, 136.44, 137.93, 
144.27, 145.19, 158.32; 31P NMR (125 MHz, CDCl3) δ 147.61 ; ESI-HRMS (ES+) m/z 
calculated for C64H93N6O5P 1056.6002, found 1056.6063 [M+H] (Hydrolyzed product). 
2.3 – Chemical Synthesis and Purification of Oligonucleotide Strands 
All reagents used in the synthesis of the oligonucleotides strands were purchased from 
Glen Research (Virginia, USA). All of the oligonucleotide strands were synthesized using an 
Applied Biosystems 394 DNA/RNA synthesizer on a 0.2 µM cycle with a 999 second 
coupling time. All reagent solutions are attached to the synthesizer directly and DNA/RNA 
phosphoramidites were diluted to 0.1 M using anhydrous acetonitrile immediately before 
use. Synthesis was carried out on a CPG solid support to which dT at 0.2 µM is attached. 




(Glen Research). Oligonucleotide cleavage from the solid supports was done by flushing the 
CPG column with 1.5 ml of EMAM (methylamine 33% wt. in ethanol and methylamine 40% 
wt. in H2O, 1:1) (Sigma-Aldrich) for 1 hour at to remove the strands from the column 
followed by an additional incubation period of 24 hours to deprotect the bases. The 
samples were then dried and resuspended in 125 µL of 3HF-Et3N (Sigma-Aldrich) and 100 
µL of DMSO and then this solution was incubated at 65 °C for 2 hours to remove the 2’-O-
TBS protecting groups. 
 The purification of the oligonucleotides begins with an EtOH precipitation followed 
by the desalting using a Millipore Amicon Ultra 3000 MW cellulose centrifugal filters. PAGE 
purification using a 40% denatured gel was done as for allyl and acetyl modified strands. 
Strands were physically excised from the gel and desalted using the centrifugal filters. 
Wild-type luciferase strands were purchased from Integrated DNA Technologies (IDT). 
Sense and antisense strands were annealed by combining equimolar amounts and heating 
at 90 oC for 2 minutes in binding buffer (75 mM KCl, 50 mM Tris-HCl, 3 mM MgCl2, pH 8.3) 
followed by the gradual cooling to room temperature over 3 hours to afford the siRNAs.  
2.4 – Biophysical Characterization 
 The siRNA samples for the biophysical characterization testing were prepared by 
adding equimolar amounts (350 pM) of modified sense strand and w.t. antisense strand 
(IDT Technologies) in an eppendorf tube. The strands were suspended in 380 µL of sodium 
phosphate buffer (90 mM NaCl, 10mM Na2HPO4, 1 mM EDTA, pH = 7) and heated to 90 °C 
for 2 minutes after which the solution was gradually allowed to cool down to room 
temperature. The siRNA samples are the transferred to a 1 mm quartz cuvette (QS) and all 
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measurements were done using a J-815 CD Spectrometer and data was recorded using 
Jasco’s Spectra Manager 2.0 software.  
2.4.1 - Helical Conformation Analysis Using Circular Dichroism 
 Circular dichroism studies were carried out at 25 °C over a wavelength range of 200 
to 300 nm scanning at a rate of 20 nm per minute. Each sample was measured four times 
and the average spectra is obtained using Jasco’s Spectra Manager 2.0 software 
2.4.2 - UV-Monitored Thermal Denaturation of siRNA Duplexs 
 Melting temperature studies were done at 260 nm and all samples were run with a 
baseline of sodium phosphate buffer. The temperature was increased from 10 °C to 90 °C at 
a rate of 0.5 °C per minute. Tm data was analyzed using Meltwin 3.5 software. The average of 
triplicate measurements is taken at the Tm of the duplex. 
2.5 Cell Culture Maintenance 
The cell line used for the biological analysis of these siRNAs is human epithelial 
cervix carcinoma cells, commonly referred to as HeLa cells. Cells were kept in cell culture 
flasks with 25 ml of DMEM modified by adding 10% fetal bovine serum (Perbio) and 1% 
Penicillin-Streptomycin (Sigma) and stored in an incubator set at 37.5 oC with a 5% CO2 
atmosphere that is humidified.   
Cells were passaged twice a week, once cells became confluent, according to the 
following protocol. The cell culture flask was washed twice with 1X phosphate buffered 
saline (PBS) with a pH of 7.4 (Invitrogen) and then incubated with 2 ml of 0.25% Trypsin 
(SAFC Bioscience) for 2 minutes at 37.5 °C. This 2 ml of cell solution was transferred to a 
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Falcon tube and diluted with 5 ml of DMEM with 10% FBS and pelleted at 1,500 rpm for 5 
minutes. The supernate was discarded and the pellet was resuspended in 10 ml of DMEM 
with 10% FBS. A haemocytometer was used obtain a cell count followed by a dilution to 
make a cell concentration of 1,000,000 cell per ml. From this 1 ml was added to a new cell 
culture flask that already contains 24 ml of DMEM with 10% FBS and 1% P/S. at 37.5 °C. 
The remaining cell solution was utilized for plating when needed. 
2.6 – Cell Based Assays 
2.6.1 – Plating and Transfection  
For the luciferase assay, 100 µl of the 1,000,000 cells per ml solution were added to 
the wells of a 12 well plate already containing 400 µL of DMEM with 10% FBS per well. For 
qRT PCR, 50 µL of the 1,000,000 cells per ml solution was added to the wells of a 24 well 
plate that already has 350 µL of DMEM with 10% FBS per well. After plates are prepared 
they were incubated at 37.5 °C with 5% CO2 for 24 hours. 
A mixture of 1µL siRNA, and 1 µL of Lipofectamine 2000 (and 100 ng of pGL and SV 
plasmid for luciferase assay) was prepared in Gibco’s Opti-Mem Reduced Serum Medium to 
a total volume of 100 µl (200 µL for Luciferase assay). A different solution is made for each 
siRNA and for every concentration. These solutions were then transferred to the well plates 
and incubated for another 24 hours.  
2.6.2 – Dual Luciferase Reporter Assay 
After the post transfection incubation period each well was washed with twice with 
1X PBS and then 250 µL 1X Passive Lysis Buffer was added to lyse the cells over a period of 
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20 minutes on a shaker. Then 10 µL cell lysate was transferred to a Costar 96 well plate 
(making triplicates of each lysate) immediately and a Synergy HT (Bio-Tek) plate 
luminometer was used to measure fluorescence. Fluorescence studies were done using the 
Dual-Luciferase Reporter Assay kit (Promega). According to the kit’s protocol, 50 µL of LAR 
II substrate was first added to induce firefly luciferase luminescence followed by the 
addition of 50 µL of Stop&Glow to quench firefly luciferase and induce Renilla luciferase 
luminescence. The firefly luciferase signal was normalized with the Renilla luciferase signal 
and the signal for the cells transfected with no siRNA were taken as 100% expression to 
which the other strands are compared.  
2.6.3 – qRT PCR Targeting the BCL2 Oncogene 
 On a 24 well plate, 50,000 cells were added to each well of a 24-well plate with 350 
µL of DMEM with 10% FBS in a 5% CO2 environment at 37 oC. After 24 hours cells were 
treated with 1 nM and 20 nM concentrations of siRNAs targeting the BCL2 oncogene using 
Lipofectamine 2000 in 1X OptiMem; each siRNA (1 µL) was added to a tube on ice along 
with 50 µL of OptiMem and combined with a second tube with 1 µL of Lipofectamine and 
50 µL of OptiMem after a period of 20 minutes. At this point there were roughly 250,000 
cells in each well and after transfection the final volume in the well in 500 µL. After 24 
hours from transfection the cells were lysed for reverse transcription which was 
accomplished using a Cells-to-cDNA II Kit (Ambion) following the manufacturer’s protocol. 
The amplification of BCL2, GAPDH, and 18S were done on a CFX96 Real-Time reactor (Bio-
Rad), using SsoFast EvaGreen Supermix (Bio-Rad) as the source of EvaGreen dye and Taq 
polymerase. Forward and reverse primers for GAPDH were added giving a final 
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concentration of 800 nM, 18S’s primers were 100 nM and the BCL2 primers were 500 nM 
bringing each reaction volume to a total of 20 µL. The GAPDH forward and reverse primers 
were 5’ – ACG GCT GCT TTT AAC TCT GG – 3’ and 5’ – TTG ATT TTG GAG GGA TCT CG – 3’ 
respectively which produced a 200 bp amplicon. The 18S forward and reverse primers 
were 5’ – CGC CTA CCA CAT CCA AGC AAG – 3’ and 5’ – CGC TCC CAA GAT CCA ACT AC – 3’ 
respectively which produced a 247 bp amplicon. The BCL2 forward and reverse primers 
were 5’ – CTG GTG GGA GCT TGC ATC AC – 3’ and 5’ – ACA GCC TGC AGC TTT GTT TC – 3’ 
respectively which produced a 150 bp amplicon. There were non-reverse transcriptase 
controls performed accompanied with a no template control. The reactor protocol was 
carried out as follows: pre-heat the chamber to 95 °C for 2 min, followed by 40 cycles of 95 
°C for 5 sec, 52 °C for 15 sec and 72 °C for 5 sec. The last step was the gradual raising of the 
temperature from 65 °C to 95 °C for the melting temperature analysis of the PCR products 
at 260 nm. The expression of BCL2 was normalized to GAPDH and 18S using the 








3.0 - Results and Discussion 
3.1 – Organic Synthesis of Phosphoramidites  
In this paper the scope of chemical modification in siRNA is expanded with the 
synthesis of modified alkyl spacer phosphoramidites and there subsequent incorporation 
in to RNA oligonucleotides. The double base linker utilizes a protection-deprotection 
strategy for modification followed by attachment of the two groups needed for DMT-
Phosphoramidite chemistry; the synthesis of the all five linkers is described herein. The 
synthesis begins with the tert-butyldimethylsilyl (TBS) protection the alcohol groups of 
N,N’- bis(2-hydroxyethyl)ethandiamine to produce 1 in a 68% yield (Scheme 3-1). The TBS 
groups are commonly used alcohol protecting groups [83] that are needed in this case to 
prevent the alcohols from becoming alkylated under basic conditions in the subsequent 
reaction. It is important to use just over two equivalents of TBS-Cl in order to only protect 
the alcohols groups and to not react the nitrogen atoms. Once the secondary nitrogens are 
the only nucleophiles left, a strong base, sodium hydride in this case, is used in combination 
with allyl bromide to alkylate the nitrogen atoms to produce 2 in a 74% yield via an SN2 
mechanism and/or through a nucleophilic attack on the alkene. Once the modification is on 
the linker the TBS groups need to come off, this was accomplished with TBAF which is an 
organic fluoride salt. The fluoride anion undergoes a nucleophilic attack on the silicon atom 
producing a pentavalent centre, which can exist due to hybridization with silicon’s vacant 
d-orbitals which will collapse breaking the Si-O bond due to the newly formed and highly 
stable Si-F bond [84] producing 3 in a 92% yield. The dimethoxytrityl protecting group is 
one of two chemical groups needed for DMT-Phosphoramidite chemistry. This group is 
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used to protect alcohols for oligonucleotide synthesis because it is quite easy to knock off 
with acid and the cation formed is highly coloured and stable, making the coupling of bases 
easy to monitor [85]. The attachment of the DMT group proved to be the least efficient step 
in the synthesis simply due to the symmetry of the molecule being protected; even though a 
single DMT group might be attached it is still very possible for the other alcohol group to 
undergo the same reaction and it was observed. This is the reason less than one equivalent 
of DMT-Cl is used in basic conditions to afford 4 in just a 46% yield. The final step is the 
attachment of the phosphite group; which is the most synthetically challenging step 
because of the sensitivity of the phosphite group towards moisture [86]. The phosphite 
group was attached to the linker using base and produced 5 in a 71% yield producing the 
phosphoramidite with an overall 15% yield. The phosphite group will become oxidized to a 
phosphate during oligonucleotide synthesis. 
 
Scheme 3-1: Synthesis of allyl modified phosphoramidite.  
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 The propargyl synthetic scheme (Scheme 3-2) is almost identical to that of the allyl 
linker. The only difference comes during the attachment of the propargyl substituents on 
the nitrogen atoms. The conditions utilized for the allyl scheme used NaH as the base; this 
base is too strong for this scheme as it is capable of deprotonating the alkyne proton (pKa 
~ 25) compared to an alkene (pKa ~ 44) [87]. Substituting the base with a weaker base, 
such as DIPEA in this case, allows for alkylation to proceed with the only downfall being a 
longer reaction time due to the equilibrium established by the base [88]. 
 
Scheme 3-2: Synthesis of propargyl modified phosphoramidite. 
 Synthesis of the acetyl linker (Scheme 3-3) was carried out the same as the allyl 
linker with the only difference coming at the alkylation of the nitrogen atoms. The 
acetylation was accomplished using DMAP as an activating agent and acetic anhydride is 
the alkylating agent. The combination of the nucleophilic character of nitrogen and the 
electron deficient character of the carbonyl group on acetic anhydride makes this a 
favourable transformation [89].  The attack of nitrogen forms a tetrahedral intermediate on 
acetic anhydride that collapses to liberate the stabilized acetate anion leaving the acetyl 
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group attached forming the amide functionality. Although this linker is being modified with 
an acetyl group it will be cleaved off during the nucleobase deprotection step leaving the 
linker with the original unmodified secondary nitrogen scaffold.  
 
Scheme 3-3: Synthesis of acetyl modified linker phosphoramidite. 
The synthesis of the small propargyl linker (Scheme 3-4) was accomplished using a 
slightly different approach than the three previous schemes due to difficulties with the TBS 
deprotection. The nitrogen was alkylated directly in the presence of five equivalents of 
weak base, K2CO3, with one equivalent of propargyl bromide to produce the product, 16, in 
a low yield [90]. After this step the DMT protection and subsequent phosphitylation are the 
same as the previous three linkers described. More details regarding the synthesis of this 
small propargyl linker can be found in Roberts, 2014 [91]. One of the purposes of attaching 
propargyl groups on to these alkyl linkers is the ease and abundance of subsequent 
modifications that can follow such as the Pd0 catalyzed Sonogashira coupling of alkynes 
with alkyl halides [92] or the CuI assisted Huisgen 1,3-dipolar cycloaddition of alkynes with 




Scheme 3-4: Synthesis of small propargyl phosphoramidite. 
 Whereas the previous four synthetic schemes have focused on simple modifications 
on the alkylamino backbone, Scheme 3-5 focuses on the further modification by 
performing chemistry on the propargyl group.  There has been a lot of focus on attaching 
biomolecules, such as cholesterol, to enhance properties such as cellular uptake; however 
the majority of such modifications tend to be found as 3’ modifications with comparatively 
few means on internal conjugation [94].A review paper published in 2012 by Efthymiou et 
al., describes how 1,2,3-triazole functionalities have been well tolerated as a nucleic acid 
modification [69] which was the route taken to attach the cholesterol group in this 
modification. A study in 2011 by Krishna and Verma described the simple synthesis of 
cholesterol with its alcohol replaced by an azide group, compound 15, which was used to 
form the linker with the triazole-linked cholesterol. To form the triazole a copper (I) 
catalyst is needed; Cu2SO4-5H2O was used instead with an in situ reducing agent, sodium 




Scheme 3-5: Synthesis of click-cholesterol phosphoramidite. 
 The reaction begins with Cu(II) being reduced to Cu(I) by sodium ascorbate, an 
excess of sodium ascorbate is used to prevent the formation of oxidative homocoupling 
products [96]. The Cu(I) compound along with the linker’s alkyne form a copper acetylide 
intermediate which is attacked by the azide at the copper center displacing a ligand. With 
the azide and alkyne within close proximity they form a six-membered copper (III) 
metallacycle which subsequently contracts in to a triazolyl-copper species that undergoes 
protonolysis to form the final product and completing the catalytic loop [97]. The synthetic 
loop can is depicted below in Figure 3-1. The method is selective in forming the 1,3 
product; if the 1,2 product was ever sought there are well established methods using a 




Figure 3-1: Cu(I) catalyzed azide-alkyne cycloaddition catalytic cycle forming the 1,3 
triazole. 
 To ensure that these phosphoramidites have been successfully into the RNA 
oligonucleotides mass spectrometry was performed on the sense strand. The results of 
which are seen in the table below.  
Table 3-1: Negative ESI of sense strand oligonucleotides. 
Strand Modification Type 
and Position 
m/z Calculated m/z Found 
P1 Propargyl (9+10) 6186 6221 
[M+Cl]- 
L1 Allyl (9+10) 6188 6223 
[M+Cl]- 
A1 Acetyl (9+10) 6070 3077 





3.2 – Thermal Stability of siRNAs 
 The siRNA helix is stabilized through two main types of interactions; 1) hydrogen 
bonding and 2) base stacking [99]. Measuring the melting temperature (Tm), the 
temperature at which point the two strands dissociate, gives insight to the duplex’s 
stability. Since nucleobases have high absorption at 260nm, measuring absorption as a 
function of temperature will allow Tm to be calculated due to the fact that the exposed 
nucleobases have higher absorption than equivalent bases in ds nucleic acid form [100]. 
Comparing the thermal stability to wild type can help shed insight on why the newly 
modified siRNAs display their activity, Table 3-1 displays the synthesized strands 

















Table 3-2: Sequences of anti-luciferase siRNAs and Tm’s of siRNAs containing the double 
base spacer. 
siRNA siRNA Duplex aTm  (oC) ΔTm (oC) 
wt 
 
           5’- C UUA CGC UGA GUA CUU CGAtt -3’ (S) 





           5’- C UUA CGC UQQ GUA CUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
55.1 -17.6 
A2            5’- C UUA CGC UGQ-QUA CUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
53.3 -19.4 
A3            5’- C UUA CGC QQA GUA CUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
54.6 -18.1 
A4            5’- C UUA CGC UGA GUQ-QUU CGAtt -3’ 





           5’- C UUA CGC ULLGUA CUU CGAtt -3’ 





           5’- C UUA CGC LLA GUA CUU CGAtt -3’ 





          5’- C UUA CGC UGL-LUA CUU CGAtt -3’ 





           5’- C UUA CGC UGA GUL-LUU CGAtt -3’ 





           5’- C UUA CGC UPP GUA CUU CGAtt -3’ 





           5’- C UUA CGC UGP-PUA CUU CGAtt -3’ 





           5’- C UUA CGC PPA GUA CUU CGAtt -3’ 





           5’- C UUA CGC UGA GUP-PUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
56.5 -16.7 
 aTms were measures in a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) 
at 260 nm, from 10 to 95 oC. QQ, LL and PP correspond to the acetyl, allyl and propargyl modified 




What does not come as a surprise when viewing the Tm’s in Table 3-2 is the introduction of 
this linker introduces a significant degree of destabilization. This is due to the removal of 
the hydrogen bonding from the two missing bases as well as the base stacking interactions 
they would also participate in [101]. For each position the linker replaces one A-U bond 
and one G-C bond which means the destabilization effects seen will not be affected by 
replacing different numbers of H-bonds. When comparing the destabilization effect to the 
study done by Efthymiou et al., in 2012, which uses the same anti-luciferase sequence and 
two nucleobase spacers, on average this new linker is displaying a higher degree of thermal 
stabilization compared to the nine-carbon linker (C9) and eight-atom polyethylene glycol 
(E8) within the central region of the sense strand [74]. A possible explanation for this could 
be that the propargyl and allyl pi electrons are somehow interacting with the base stacking 
interactions which may be imparting a small degree of stabilization; when examining the 
Tm’s of the acetyl modified strand it is apparent that this interaction is not possible and 
destabilization is comparable to what was observed by Efthymiou et al., in 2012. When 
examining the data there is a trend emerging, the linker imparts the least amount of 
destabilization when occupying the Argonaute2 cleavage site or the immediately adjacent 
sites while the modification at position 13 and 14 destabilized by a few more degrees 
which has been observed in several other modifications [101].  
 In Table 3-3 shown below, the thermal destabilization of the smaller linker that 
replaces a single nucleobase is assessed. Again with no surprise the table shows that 
introduction of this linker results in destabilization of the duplex due to the same reasons 
as the longer spacer. The propargyl spacer when compared to its longer version is roughly  
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Table 3-3: Sequences of anti-luciferase siRNAs and Tm’s of siRNAs containing the single 
base spacer. 
siRNA siRNA Duplex aTm  (oC) ΔTm (oC) 
wt 
 
           5’- C UUA CGC UGA GUA CUU CGAtt -3’ (S) 
          3’- ttG AAU GCG ACU CAU GAA GCU – 5’(AS) 
 
72.7 -- 
BR1            5’- C UUA CGC UPA GUA CUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
69.1 -2.8 
BR2            5’- C UUA CGC UGP GUA CUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
70.2 -2.5 
BR3            5’- C UUA CGC PGA GUA CUU CGAtt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
67.7 -5.0 
BR4            5’- C UUA CGC UGA PUA CUU CGAtt -3’ 





           5’- C UUA CGC UXAGUA CUU CGAtt -3’ 





           5’- C UUA CGC UGX GUA CUU CGAtt -3’ 





           5’- C UUA CGC XGA CUA CUU CGAtt -3’ 





           5’- C UUA CGC UGA XUA CUU CGAtt -3’ 





           5’- C UUA CGC UGA GUA CUU CGAXt -3’ 
3’- ttG AAU GCG ACU CAU GAA GCU – 5’ 
 
69.8 -2.9 
 aTms were measures in a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) 
at 260 nm, from 10 to 95 oC. P and X correspond to the propargyl and click-cholesterol modified 
spacer respectively. ‘ __ ‘ Shows the position of the Ago2 cleavage site.  
  
 
half as destabilizing, which makes sense as there is only one abasic site as opposed to there 
being two. The click cholesterol linker displays destabilization similar to the allyl modified 
double spacer; although the linker replaces a single base the introduction of the large 
cholesterol group is surely imparting some steric effects on the duplex which is most likely 
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the main reason for destabilization. This agrees with the literature where internal 
cholesterol modifications tend to be quite destabilizing [102].  The click cholesterol 
modification on the 3’ overhang however displays minimal destabilization as the linker is 
lying just outside of the duplex therefore destabilizing it to a lesser extent compared to all 
the other positions which agrees with what is seen in the literature [103].  
3.3 - Circular Dichroism Conformation of siRNA Helical Structure 
 In order for siRNAs to retain activity they must be in the A-form helical 
conformation to be able to be a tolerable substrate for RISC [104]. By interacting 
asymmetrical molecules with polarized light distinct absorption patterns arise which can 
be used to identify secondary structures in nucleic acids [105]. One such example is the 
absorption profiles for A-form helices which are depicted in Figure 3-2 to Figure 3-4.  
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Figure 3-2: CD spectra of modified linkers replacing two nucleobases targeting firefly 




 Each helical conformation (A, B and Z form) has a distinct absorption profile. A-form 
has a distinct shallow trough at ~210nm and a large absorption at ~260nm with the B-
form helices exhibiting a similar profile except the aforementioned are values shifted to 
220nm and 280nm respectively [106]. CD is a very useful technique for assessing the 
interactions of chemically modified nucleotides are their complementary sequences as any 
change in molar ellipticity is attributed primarily to the change in the conformation of the 
complex [107]. Examination of the three figures shows some deviation of the spectral plots 
from w.t., this is seen with several chemically modified due to the fact that the introduced 
chemical groups slightly distort the helical conformation which can be seen in the shift of 
λmax around 260nm [107]. The shifts seen in Figures 3-2 to 3-4 however are not significant 
enough to distort the overall shape from the A-form helix [106]. 
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Figure 3-3: CD Spectra of propargyl and click-cholesterol spacers replacing a single 


























Figure 3-4: CD spectra of propargyl and allyl modified spacers replacing two nucleobases 
for the anti-BCL2 sequences. 
Inspection of the CD spectra reveals that this linker retains the over A-form helical 
conformation as the characteristic trough is present at 210nm and large absorption at 
267nm meaning that the modification does not disrupt the native conformation meaning 
this modification should be suitable for RNAi.  
3.4 – Silencing Capability of the Endogenous Firefly Luciferase Gene 
 The biophysical characterization of the modified siRNAs has revealed traits that 
suggest they should be compatible with RNAi. The dual luciferase assay is a widely used 
assay that is used in this case to screen the new modifications for position and 
concentration dependant gene silencing activity. The siRNAs will target firefly luciferase 
mRNA while Renilla luciferase (expressed via the pGL10 and SV40 plasmids) expression 
will be used to normalize the signal. Both luciferase enzymes catalyse a reaction that 
produces light as one of the products [108] which will be used to assess expression levels 
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via luminescence intensity [109]. The controls for the HeLa cell studies were cell 
transfected with the plasmids with no siRNA to which luminescence is expressed as a 
percent. The results are seen in the Figures 3-5 to 3-7 with the siRNAs being tested at 
three different concentrations. 
 
Figure 3-5: Gene silencing capability of HeLa cells treated with propargyl modified linker 
siRNA targeting firefly luciferase mRNA and normalized to Renilla luciferase. 
The first four strands tested (siRNAs P1 – P4) contain the propargyl modified spacer 
(Figure 3-5) that spans two nucleobases. Comparing the modified strands to wt it becomes 
clear that the linker is well tolerated within the central even though it imparts 
destabilization (P1 – P3), which agrees with the work put forth by Maier et al., in 2010. 
Activity is very close to wt at the 800 pM concentration however activity decreases fast 
compared to wt as the concentration drops for strands P3 and P4. A possible explanation 
for the drop in activity compared to wt is the Tm of the modified strands which shows 






























duplex compared to wt [110].  Even when the linker is placed toward the 3’ end of the 
sequence (P4) activity is still retained. Although this position isn’t in the center it 
contributes to destabilizing the 5’ of the desired antisense strand which has been shown to 
increase strand selection accuracy [111]. 
 
Figure 3-6: Gene silencing capability of HeLa cells treated with allyl modified linker siRNA 
targeting firefly luciferase mRNA and normalized to Renilla luciferase. 
The allyl modified linker (siRNAs L1 – L4) activity (Figure 3-6) displayed very similar 
activity to that of the propargyl modified linker which is not surprising as the modifications 
are very similar. Again the centrally located linkers (siRNAs L1 – L3) display excellent 
silencing capability at 800 pM and decreased activity compared to wt at decreasing 
concentrations. 
The final modification for the linker spanning two nucleobases is the bare linker 
(siRNAs A1 – A4), which used acetyl protecting groups during all the syntheses. Overall this 






























destabilization effect on the siRNA duplexes. One major difference compared to the 
previous two modifications is that the linker spanning the Argonaute2 site (A1) displays 
the least effective gene silencing capability at 800 pM which is the highest concentration 
that was tested.  
 
 
Figure 3-7: Gene silencing capability of HeLa cells treated with acetyl modified linker 
siRNA targeting firefly luciferase mRNA and normalized to Renilla luciferase.  
One possibility for these strands having comparable potency to wt could be that it is 
believed this type of destabilization aides in the unwinding of dsRNA [111].  When taking 
each of the three modifications it is shown that the linkers that span the Argonaute2 
cleavage sites (A1, L1 and P1) are silencing gene expression even though the linker is most 
likely not being cleaved. This agrees with the findings of Efthymiou et al., in 2012 and Maier 
et al., 2010. An explanation for these results could be that Argonaute2 site destabilization 






























of sense strand dissociation [112] as opposed to the cleavage mechanism. It has been 
shown that other than terminal asymmetry of the RNA duplex, lowered central duplex 
stability is directly correlated with increased siRNA potency [113]. In their study targeting 
two different anti-luciferase mRNA Maier et al., determined position 10 on the sense strand 
showed the best potency in terms of introducing site specific destabilization [50]. 
Examination of the luciferase knock-down figures the linkers that spanned positions 10+11 
(siRNAs A2, L3, and P2) were the most potent or very close to at 800 pM, however activity 
worsens at the two lower concentrations with the propargyl modification retaining activity 
comparable to wt over each concentration. The linkers spanning the Argonaute2 site 
(siRNAs A1, L1, and P1) displayed mixed results with the propargyl modification being well 
tolerated at each concentration whereas the acetyl linker being one of the poorest gene 
silencers when taking each modification position into consideration. When Maier et al., 
replaced the Argonaute2 cleavage site with a destabilizing factor potency was increased 
~2.5 fold; this was not the case with this two nucleobase linker and is most likely due to the 
fact that this modification imparts much greater destabilization which is most likely 
hindering its ability to some extent. The final linkers to be assessed are the single 
nucleobase (siRNAs BR 1-4 and X 1-5) replacing linker featuring a propargyl or click-
cholesterol modification (Figure 3-8). 
With the excellent activity of the larger spacer it does not come as a surprise that the 
siRNAs that contain the smaller spacers (siRNAs BR 1-4 and X 1-5) also display potent 
gene-silencing activity even when compared to w.t. Even the internally conjugated 
cholesterol modified siRNAs can display potent gene silencing capabilities whereas most 
internal cholesterol modified siRNAs generally display significantly decreased activity 
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which is thought to occur as the large cholesterol group may be interfering in key 
interactions within RISC [114]. Being attached on an alkyl backbone however gives the 
cholesterol group quite a bit a freedom to move around and potentially adopt a position 
that allows for these key interactions to proceed relatively unhindered. 
 
Figure 3-8: Gene silencing capability of HeLa cells treated with small propargyl and click-
cholesterol modified siRNA targeting firefly luciferase mRNA and normalized to Renilla 
luciferase. 
The siRNA modified with the cholesterol at the 3’ end (X5) retained the best activity 
over all three concentrations. Not only can 3’ destabilizing modifications increase antisense 
strand selection by destabilizing the antisense 5’ end  the linker also enhances cell 
membrane permeability due to the cholesterol group [115]. Since this group is also 
attached on the overhang there isn’t much duplex destabilization which also contributes to 






























Thinking back to the study by Maier et al., in 2010 the site specific abasic 
modifications do not appear to increase potency as previously reported within the central 
region [50], even at position 10 of the sense strand. Comparing the propargyl modified 
small linker siRNAs (siRNAs Br 1- 4) they display activity comparable if to w.t. at 800 pM 
while retaining better activity over the two smaller concentrations compared to the linker 
replacing two nucleobases which is most likely attributed to the lesser extent of thermal 
destabilization.  
3.5 – Silencing Capability of the Clinically Relevant BCL2 Oncogene 
 Although the dual luciferase assay is a decent screening method for new 
modifications it does not accurately represent the potency because an abundant exogenous 
mRNA sequence is being targeted as opposed to many problematic genes, such as 
oncogenes, which exist at expression levels folds less than the luciferase mRNA [117]. The 
BCL2 oncogene has been directly implicated in several major cancers because damage to 
this gene can result in anti-apoptosis [118]. With the propargyl and allyl modified two 
nucleobase spacers having excellent activity in the central region of the sense strand those 
positions and modifications were chosen to target BCL2, the sequences of which are shown 
in Table 3-3 below.  
 In order to assess the gene silencing capability of the anti-BCL2 siRNAs the 
expression levels of need to assessed against control genes. For this study the GAPDH and 
18S genes will be used at the controls as each are very well characterized and have been 
used extensively in literature for PCR work [119].  To ensure that the primers were not 
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forming any products a no-template control was run along with a no-reverse transcriptase 
control to ensure no genomic contamination [120].  
Table 3-4: Sequences of anti-BCL2 siRNAs containing the double base spacer and their 
melting temperatures.  
siRNA siRNA Duplex 
 




5’ – GUG AAG UCA ACA UGC CUG Ctt – 3’ (S) 





5’ – GUG AAG UCX-XCA UGC CUG Ctt – 3’ 





5’ – GUG AAG UXX ACA UGC CUG Ctt – 3’ 





5’ – GUG AAG UCA XXA UGC CUG Ctt – 3’ 





5’ – GUG AAG UCL-LCA  UGC CUG  Ctt – 3’ 





5’ – GUG AAG ULL ACA UGC CUG Ctt – 3’ 




5’ – GUG AAG UCA LLA UGC CUG Ctt – 3’ 
3’ – ttCAC UUC AGU UGU ACG GAC G – 5’ 
72.6 -9.1 
   
aTms were measures in a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) at 
260 nm, from 10 to 95 oC. XX and LL correspond to the propargyl and allyl modified spacer 
respectively. ‘ __ ‘ Shows the position of the Ago2 cleavage site. 
  
 
Examining the gene silencing data in Figure 3-9 shows that this linker is extremely well 
tolerated within the central region when targeting an endogenous gene. What immediately 
stands out is that the modified siRNAs (P5 – P7 and L5 – L7) have greater activity than wild 
type at the 1 pM concentration which was not seen in the anti-luciferase trials but agrees 
more with the finding put out by Maier et al., in 2010. Another noticeable difference from 
the anti-luciferase trials is that the siRNAs exhibiting the best potency across all 
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concentrations appear to be the linkers spanning the Argonaute2 site (P5 and L5). 
Examining the sequences in Table 3-3 shows that when the linker is spanning the 
Argonaute2 site for this sequence two A-U bonding interactions are disrupted, which totals 
only 4 H-bonds, whereas the other two modification sites (siRNAs P6, P7, L6 and L7) 
replace on A-U and one G-C bonding interaction, totalling 5 H-bonds. This most likely 
means that the Argonaute2 site modified siRNAs (P5 and L5) are introducing less 
destabilization than the other two positions which is seen in the gene silencing ability of 
the siRNAs [121].  
 
Figure 3-9: BCL2 oncogene knock-down using allyl and propargyl modified siRNAs 
assessed using qRT-PCR using 18s and GAPDH as controls. 
Although the introduction of these linkers imparts a significant degree of 
destabilization on siRNA duplexes the aforementioned results show that this 


































of the sense strand. With extremely promising results targeting exogenous and endogenous 















4.0 - Future Directions 
 With the success of the silencing capability of the modified alkyl linkers there is no 
doubt that this project should be pursued farther in terms of expanding the scope of this 
type of modification. To do this however there should be some synthetic optimization, 
particularly at the TBS protection step. The yield obtained is modest, which occurs when 
straightforward alcohol TBS protection is attempted in basic conditions; however by 
utilizing 2.5 equivalents (eq) of imidazole and 1.2 eq of TBS-Cl per alcohol group in DMF 
yields can be greatly increased [122]. This could potentially raise the overall synthesis yield 
by upwards of 7%.  
 With the successful introduction of simple modifications on this linker the logical 
next step would be utilizing those modifications to affix other modifications. An example of 
this would be performing a Sonogashira coupling reaction with the alkyne linkers and 
iodouracil which would help in trying to fine tune the destabilization by introducing 
controlled addition of H-bonding in to the duplex. Conjugating more biomolecules would 
also be another interesting avenue to explore such as trying to turn the larger propargyl 
linker in to a x2 click cholesterol linker which would make an interesting 3’ overhang 
modification on the sense strand as cholesterol modifications are well tolerated in this 
region [115]. 
 Although these linkers presented herein displayed excellent knockdown 24 hours 
after transfection it is entirely possible that the maximum knockdown is occurring at some 
other time [123].  A time-dependency analysis should be performed to determine when the 
 
71 
optimal knockdown is occurring which should then be implemented in to the procedure for 
testing the siRNAs to determine optimal knockdown.  
 Another useful test that could be done would be a simple incubation experiment 
without a transfection agent to see if the introduction of the two protonated nitrogen 
atoms can facilitate crossing of the cellular membrane. This is a common simple study done 
with modified siRNAs that are designed to increase cell membrane permeability, such as 
cholesterol modifications [124]. This study would be of particular interest with the single 
click cholesterol which not only possesses the positively charged nitrogen but also the 
lipophilic cholesterol moiety. The cell permeability could be increased even further if 
multiple click cholesterol modifications were incorporated; examining the thermal stability 
of the single click cholesterols the incorporation of the 3’ overhang modification as well as 










5.0 - Conclusion 
 This study presents a simple and novel means of central region destabilization 
through sense strand modification in siRNAs through the use of modifiable alkylamino 
linkers. Even when the non-cleavable linkers span the catalytic region of the Argonaute2 
catalytic site activity is retained that is comparable to wild type. In the case of silencing the 
clinically relevant BCL2 oncogene, siRNAs with the modified linkers demonstrated that 
they are capable of greater gene silencing at lowered concentrations wild type indicating 
that the modification is imparting favourable characteristics upon siRNAs. The single and 
double nucleobase modified linkers show their applicability by introducing site-specific 
destabilization which can be strategically used to retain or enhance potency compared to 
wild type. With these promising preliminary results there is no doubt that further 
modification and introduction of newer simple modifications should be explored in an 
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A1-1: 1H NMR Spectrum of N,N’-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)ethane-1,2-
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A4-1: 1H NMR spectrum of 2-(allyl(2-(allyl(2-(bis(4 -
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A5-1: 1H NMR spectrum of 2-(allyl(2-(allyl(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)amino)ethyl)amino)ethyl (2-cyanoethyl) 




A5-2: 13C NMR spectrum of 2-(allyl(2-(allyl(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)amino)ethyl)amino)ethyl (2-cyanoethyl) 






A5-3: 31P NMR spectrum of 2-(allyl(2-(allyl(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)amino)ethyl)amino)ethyl (2-cyanoethyl) 











A6-1: 1H NMR spectrum of N,N’-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)-N,N’-di(prop-2-





A6-2: 13C NMR spectrum of N,N’-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)-N,N’-di(prop-2-





A7-1: 1H NMR spectrum of 2,2'-(ethane-1,2-diylbis(prop-2-yn-1-ylazanediyl))bis(ethan-1-
ol) – Compound (7) 
 
A7-2: 13C NMR spectrum of 2,2'-(ethane-1,2-diylbis(prop-2-yn-1-ylazanediyl))bis(ethan-1-






A8-1: 1H NMR spectrum of 2-((2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-
2-yn-1-yl)amino)ethyl)(prop-2-yn-1-yl)amino)ethan-1-ol – Compound (8) 
 
A8-2: 13C NMR spectrum of 2-((2-((2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-yn-1-yl)amino)ethyl)(prop-2-yn-1-





A9-1: 1H NMR spectrum of 2-((2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-
2-yn-1-yl)amino)ethyl)(prop-2-yn-1-yl)amino)ethyl (2-cyanoethyl) 
diisopropylphosphoramidite – Compound (9) 
 
A9-2: 13C NMR spectrum of 2-((2-((2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-yn-1-yl)amino)ethyl)(prop-2-yn-1-





A9-3: 31P NMR spectrum of 2-((2-((2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-yn-1-yl)amino)ethyl)(prop-2-yn-1-










A10-1: 1H NMR spectrum of N,N'-(ethane-1,2-diyl)bis(N-(2-((tert butyldimethylsilyl) 




A10-2: 13C NMR spectrum of N,N'-(ethane-1,2-diyl)bis(N-(2-((tert butyldimethylsilyl) 
















A12-1: 1H NMR Spectrum of N-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-N-(2-(N-
(2-hydroxyethyl)acetamido)ethyl)acetamide – Compound (12) 
 
 
A12-2: 13C NMR spectrum of N-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-N-(2-(N-




A13-1: 1H NMR spectrum of Synthesis of 2-(N-(2-(N-(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)acetamido)ethyl)acetamido)ethyl (2-cyanoethyl) 





A13-2: 13C NMR spectrum of Synthesis of 2-(N-(2-(N-(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)acetamido)ethyl)acetamido)ethyl (2-cyanoethyl) 




A13-3: 31P NMR spectrum of Synthesis of 2-(N-(2-(N-(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)acetamido)ethyl)acetamido)ethyl (2-cyanoethyl) 
















A17-1: 1H NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-
yn-1-yl)amino)ethan-1-ol – Compound (17) 
 
 
A17-2: 13C NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-






A18-1: 1H NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-




A18-2: 13C NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-






A18-3: 31P NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(prop-2-











A19-1: 1H NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)((1-
(((3R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-





A19-2: 13C NMR spectrum of 2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)((1-
(((3R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-



























diisopropylphosphoramidite – Compound (20) 
